Skip to main content

Evolent Health Inc

For the period ended Dec 31, 2023. Filed Feb 23, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 23, 2024

EVH$4.80+1.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Statements of Changes in Mezzanine and Shareholders’ Equity

EVOLENT HEALTH, INC.
CONSOLIDATED STATEMENTS OF CHANGES IN MEZZANINE AND SHAREHOLDERS’ EQUITY
(in thousands)
Mezzanine Equity · Shareholders’ Equity
Series A Preferred Stock · Class A Common Stock · Additional Paid-In Capital · Accumulated Other Comprehensive Loss · Retained Earnings (Accumulated Deficit) · Treasury Stock · Total Shareholders' Equity
Shares · Amount · Shares · Amount
Balance as of December 31, 2020—$—85,895$859$1,229,320$(278)$(589,178)$(21,123)$619,600
Stock-based compensation expense————16,711———16,711
Exercise of stock options——1,4901513,274———13,289
Restricted stock units vested, net of shares withheld for taxes——4925(3,855)———(3,850)
Shares issued for acquisition——1,7711856,608———56,626
Conversion of 2021 Notes——1,0951128,481———28,492
Class A common stock issued for payment of earn-outs——16—450———450
Foreign currency translation adjustment—————(84)——(84)
Net loss attributable to common shareholders of Evolent Health, Inc.——————(37,601)—(37,601)
Balance as of December 31, 2021——90,7599081,340,989(362)(626,779)(21,123)693,633
Cumulative-effect adjustment from adoption of ASC 2020-06————(106,172)—39,789—(66,383)
Stock-based compensation expense————33,981———33,981
Exercise of stock options——65164,446———4,452
Restricted stock units vested, net of shares withheld for taxes——4965(7,091)———(7,086)
Leveraged stock units vested, net of shares withheld for taxes——4595(11,237)———(11,232)
Exchange of 2024 Notes——5,39454101,803———101,857
Shares issued for acquisition——3,74237130,138———130,175
Foreign currency translation adjustment—————(816)——(816)
Net loss attributable to common shareholders of Evolent Health, Inc.——————(19,164)—(19,164)
Balance as of December 31, 2022——101,5011,0151,486,857(1,178)(606,154)(21,123)859,417
Stock-based compensation expense————40,501———40,501
Exercise of stock options——1,4061412,505———12,519
Restricted stock units vested, net of shares withheld for taxes——6306(11,323)———(11,317)
Performance stock units vested, net of shares withheld for taxes——2022(3,977)———(3,975)
Leveraged stock units vested, net of shares withheld for taxes——1,04010(10)————
2024 Note conversion——1,2941323,060———23,073
Shares issued for acquisition——8,47585261,186———261,271
Class A common stock issued for payments of earn-outs——877928,542———28,551
Issuance of series A preferred stock, net of issuance costs175168,000———————
Foreign currency translation adjustment—————(79)——(79)
Net loss attributable to common shareholders of Evolent Health, Inc.—10,427——(29,220)—(113,040)—(142,260)
Balance as of December 31, 2023175178,427115,4251,154$1,808,121$(1,257)$(719,194)$(21,123)$1,067,701
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.